Search Results
Your search for ,NOt matches 22378 pages
Showing 2151 - 2200Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC: 5-Year Outcomes From Phase III CROWN Trial
In an article in the Journal of Clinical Oncology, corresponding author Benjamin J. Solomon, MBBS, BS, PhD, of Peter MacCallum Cancer Centre, Melbourne, and colleagues provided a long-term analysis of 5-year outcomes from the phase III CROWN trial.1 Median progression-free survival had not been...
FDA Approves Immunotherapy for Relapsed or Refractory CTCL
On August 8, the U.S. Food and Drug Administration (FDA) approved denileukin diftitox-cxdl (Lymphir), a novel immunotherapy for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy. Denileukin diftitox is...
Efficacy of a JAK2/mTOR Inhibitor Combination in Controlling Acute Graft-vs-Host Disease
Adding a Janus kinase 2 (JAK2) inhibitor to standard immunosuppressive drugs may not improve prevention of acute graft-vs-host disease in patients with hematologic malignancies undergoing treatment with allogeneic hematopoietic cell transplantation, according to a recent study published by Pidala...
Cancer Screening Estimated to Cost $43 Billion Annually in United States
Cancer screening may cost more than $40 billion annually in the United States, according to a recent study published by Halpern et al in the Annals of Internal Medicine. Study Methods and Results In the recent modeling study, investigators used national health-care survey and cost resources data to ...
FDA Approves IDH1/2 Inhibitor for Certain Patients With Astrocytoma or Oligodendroglioma
The U.S. Food and Drug Administration (FDA) has approved vorasidenib (Voranigo), an isocitrate dehydrogenase-1 (IDH1) and -2 (IDH2) inhibitor, for adult and pediatric patients aged 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, following...
Active Surveillance May Enable Patients With Esophageal Cancer to Delay or Avoid Surgery
Although esophageal cancer in the United States is relatively rare—affecting about 22,400 people each year and making up about 1% of all cancer cases—the disease is common in East and Central Asian countries. Nearly 90% of patients with esophageal cancer in Asia are diagnosed with the squamous cell ...
Selpercatinib in East Asian Patients With RET Fusion–Positive NSCLC: LIBRETTO-431
Lung cancer is the leading cause of cancer-related death worldwide, accounting for the highest mortality rates among both men and women. Most lung cancers—between 80% and 85%—are non–small cell lung cancer (NSCLC), and between 1% and 2% of patients are diagnosed with RET-altered NSCLC. The results...
Adjuvant Dabrafenib Plus Trametinib for Stage III BRAF V600–Mutated Melanoma: Final Results of the COMBI-AD Trial
Georgina V. Long, MD, PhD, of the Melanoma Institute Australia and the University of Sydney, and colleagues reported the final follow-up analysis of the phase III COMBI-AD trial at the 2024 ASCO Annual Meeting (Abstract 9500) and published their findings in The New England Journal of Medicine.1...
Should Low-Dose CT Screening Be Recommended for Those at Low Risk for Lung Cancer?
Lung cancer remains the leading cause of cancer-related deaths worldwide. Detecting this disease in its early stages significantly improves survival rates, making low-dose computed tomography (CT) screening an essential component in the fight against lung cancer. Recent studies, particularly from...
Daily E-Cigarette Use May Be Linked to Higher Combustible Cigarette Cessation
U.S. adults who use e-cigarettes daily and smoke combustible cigarettes may be more likely to quit smoking traditional cigarettes compared with those who smoke but use e-cigarettes less frequently, according to a recent study published by Kasza et al in JAMA Network Open. The findings suggest that...
EGFR-Mutated NSCLC: Tepotinib/Osimertinib in Patients With MET Amplification
In the phase II INSIGHT 2 trial reported in The Lancet Oncology, Yi-Long Wu, MD, and colleagues found that the combination of tepotinib plus osimertinib showed clinically meaningful activity in patients with advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) with MET...
Sacituzumab Govitecan in Advanced Endometrial Cancer
As reported in the Journal of Clinical Oncology by Alessandro D. Santin, MD, and colleagues, findings in the endometrial cancer cohort of the phase II multicohort TROPiCS-03 trial indicated activity of the Trop-2–directed antibody-drug conjugate sacituzumab govitecan-hziy in pretreated patients...
Common Blood Tests May Improve Early Cancer Diagnosis
The results of routine blood tests could be used to speed up cancer diagnoses among patients with abdominal symptoms, according to a recent study published by Rafiq et al in PLOS Medicine. Background Most patients who report symptoms of abdominal pain or bloating to their physicians are referred...
FDA Grants Accelerated Approval to T-Cell Therapy for Unresectable or Metastatic Synovial Sarcoma
On August 2, the U.S. Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel (Tecelra), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, for adults with unresectable or metastatic synovial sarcoma who have ...
FDA Expands Endometrial Cancer Indication for Dostarlimab-gxly With Chemotherapy
On August 1, the U.S. Food and Drug Administration (FDA) approved dostarlimab-gxly (Jemperli) with carboplatin and paclitaxel, followed by single-agent dostarlimab, for adults with primary advanced or recurrent endometrial cancer. Dostarlimab was previously approved in July 2023 with carboplatin...
Extranodal Marginal Zone Lymphoma: Is Overtreatment Common?
Most patients with extranodal marginal zone lymphoma (MZL) are overtreated, according to Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland and Institute of Oncology Research in Bellinzona and the Università della Svizzera Italiana in Lugano. “Aggressive therapy is not needed in...
Liver Transplantation vs Standard Therapies in Patients With Colorectal Cancer Liver Metastasis
Certain patients with colorectal cancer that has metastasized to the liver may experience improved progression-free survival with liver transplantation compared with standard therapies, according to a recent study published by Byrne et al in JAMA Surgery. Background Colorectal cancer often...
Education Level, Social Media Awareness May Be Linked to Cancer Fatalism
Investigators have found that patients with a lower level of education and social media awareness may hold more fatalistic beliefs about cancer compared with those who are more skilled at finding information through social media, according to a recent study published by Stimpson et al in Cancer...
Gynecologic Oncologist Lynette Ann Denny, MD, PhD, Dies at Age 66
The global oncology and public health communities are mourning the death of Lynette Ann Denny, MD, PhD, a world-renowned gynecologic oncologist and a leading researcher in the prevention of cervical cancer in low-resource settings. Dr. Denny died on June 9, 2024, in Cape Town, South Africa, of...
Early-Stage Breast Cancer: MammaPrint Prediction of Extended Letrozole Benefit
In an analysis from the NRG Oncology/NSABP B-42 trial reported in the Journal of Clinical Oncology, Priya Rastogi, MD, and colleagues found that the 70-gene MammaPrint assay findings did not predict the distant recurrence benefit of extended letrozole therapy vs placebo in patients with...
Can Mutations in DNA Damage Repair Genes Predict Cisplatin Response in Muscle-Invasive Urothelial Carcinoma?
The presence of a mutation in any one of three genes known to be involved in DNA damage repair may be associated with complete pathologic response to cisplatin-based neoadjuvant chemotherapy, as measured by pathologic downstaging at the time of cystectomy in patients with muscle-invasive urothelial ...
FDA Approves Daratumumab and Hyaluronidase-fihj With VRd for Multiple Myeloma
On July 30, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for induction and consolidation in patients with newly diagnosed multiple myeloma who are eligible for...
Advanced NSCLC: Association of Intratumoral Escherichia With Overall Survival
In a study reported in the Journal of Clinical Oncology, Arielle Elkrief, MD, and colleagues found that detection of intratumoral Escherichia was associated with improved overall survival in patients with advanced non–small cell lung cancer (NSCLC) receiving single-agent immune checkpoint inhibitor ...
Cancer Research and Care Beyond Borders for Global Oncologist Dario Trapani, MD
In this installment of The ASCO Post’s Living a Full Life series, I interviewed Dario Trapani, MD, a medical oncologist at the European Institute of Oncology, Milan and Assistant Professor at the Department of Oncology and Haemato-Oncology of the University of Milan, in Italy. Dr. Trapani is a...
Key Immune Cells for Combating Aggressive Merkel Cell Carcinoma Uncovered
Researchers may have uncovered why some patients with Merkel cell carcinoma do not respond to immune checkpoint blockade therapy, according to a recent study published by Reinstein et al in Cancer Discovery. Background Merkel cell carcinoma—a rare but highly aggressive type of skin cancer—is known...
Fecal Microbiota Transplant May Help Patients With Gastrointestinal Cancers Overcome Immunotherapy Resistance
Fecal microbiota transplants may improve the effectiveness of immunotherapy in patients with gastrointestinal cancers, according to a recent study published by Kim et al in Cell Host & Microbe. Background Although immune checkpoint inhibitors have revolutionized cancer treatment, many patients...
Baseline Bone Pain and Survival in Newly Diagnosed Prostate Cancer
In an analysis from the SWOG-1216 trial reported in JAMA Network Open, Gebrael et al found that the presence of bone pain at diagnosis was associated with poorer progression-free and overall survival in patients with newly diagnosed metastatic hormone-sensitive prostate cancer. Study Details In the ...
Guardant Health’s Shield Blood Test Approved by the FDA as a Primary Screening Option for Colorectal Cancer
On July 29, the U.S. Food and Drug Administration (FDA) approved Guardant Health’s Shield blood test for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. It is the first blood test to be approved by the FDA as a primary screening option for...
Risk of Breast Cancer May Be Lower Within First 10 Years Following Ovarian Cancer Diagnosis
Patients with BRCA1- or BRCA2-mutated ovarian cancer may have a lower risk of developing breast cancer following treatment, according to a recent study published by Evans et al in Genetics in Medicine. Background Previous research has estimated that the risk of developing breast cancer by the age...
Does Bilateral Mastectomy for Unilateral Breast Cancer Impact Mortality?
The results of a contemporary U.S. population–based cohort study published by Giannakeas et al in JAMA Oncology revealed that patients with unilateral breast cancer had an increased risk of breast cancer–related death after developing contralateral disease. Although the findings also showed a...
Update on Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial in Patients With Breast Cancer
Guest Editor’s Note: Chemotherapy and its side effects can lead to decreased physical activity and poor diet quality, resulting in unfavorable changes in physical functioning and quality of life. However, adopting healthy behaviors during cancer treatments can be challenging because of physical,...
Cancer Risk From Exposure to Pesticides May Be Comparable to Risk From Smoking, Study Finds
Agricultural pesticides may carry a similar risk as smoking for some types of cancers, according to a recent study published by Gerken et al in Frontiers in Cancer Control and Society. Background In modern agriculture practices, pesticides are essential to ensure high enough crop yields and food...
Cancer and Fatherhood: A Story of Personal Power in the Face of a Mortal Disease
Iron Dad: A Cancer Survivor’s Story of Discovering Strength, Life, and Love Through Fatherhood by Paul Weigel is an inspiring and deeply moving memoir that transcends the traditional boundaries of parenthood and personal transformation. This story begins with a sense of discontent and a desire for...
Addition of Ibrutinib to Immunochemotherapy and ASCT Improves Survival in Mantle Cell Lymphoma
As reported in The Lancet by Martin Dreyling, MD, PhD, of Ludwig Maximilian University Hospital Munich, and colleagues, results in the European Mantle Cell Lymphoma Network phase III TRIANGLE trial indicate that the addition of ibrutinib to immunochemotherapy and autologous stem cell...
Phase II Study Shows Activity for Novel Targeted Agent in KRAS G12C–Mutated NSCLC
The oral KRAS G12C inhibitor glecirasib has emerged as a therapeutic option for previously treated KRAS G12C–mutated non–small cell lung cancer (NSCLC). It may potentially improve efficacy and tolerability compared with current U.S. Food and Drug Administration–approved agents, according to data...
Updated ASCO Guidance on Cancer-Related Fatigue Expands Patient Options for Interventions
A new update to the ASCO guideline on managing cancer-related fatigue recommends that health care providers urge their patients to exercise, as well as use cognitive-behavioral therapy and mindfulness-based programs to help prevent and treat this prevalent symptom.1 It is estimated that between 30% ...
Amivantamab-vmjw in NSCLC With EGFR Exon 20 Insertion Mutations
On March 1, 2024, amivantamab-vmjw (Rybrevant) was approved for use with carboplatin and pemetrexed for first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by a U.S. Food and Drug Administration...
Triplet Combination Improves Survival in Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Third-Line Setting
The anti-CD30 antibody-drug conjugate brentuximab vedotin is a standard of care for certain types of lymphomas, including classical Hodgkin lymphoma in combination with multiagent chemotherapy. Brentuximab vedotin has also shown efficacy and safety in combination with lenalidomide and rituximab in...
ESOPEC Trial: FLOT Protocol Proves Superior to CROSS Regimen in Locally Advanced Esophageal Cancer
The phase III ESOPEC trial, conducted in Germany, compared two regimens for locally advanced esophageal cancer and found an overall survival benefit with the perioperative FLOT protocol over the neoadjuvant chemoradiotherapy CROSS regimen. The results were presented during the Plenary Session of...
Failure to Diagnose and Statutes of Limitations: Lavern’s Law and Its Implications for Oncology
When health-care providers, including oncologists, fail to promptly diagnose a medical condition or communicate their diagnosis to their patients, it can have devastating consequences for those patients. In such cases, patients may seek legal recourse through medical malpractice lawsuits, creating...
Two Phase III Trials Report Benefit With Isatuximab-Based Regimens in Newly Diagnosed Multiple Myeloma
In newly diagnosed, transplant-ineligible patients with multiple myeloma, treatment with the anti-CD38 monoclonal antibody isatuximab plus bortezomib, lenalidomide, and dexamethasone (VRd) led to a 40% reduction in the risk of disease progression or death and “deep and sustained responses,” almost...
Neoadjuvant Camrelizumab Plus Apatinib in Locally Advanced Colorectal Cancer
In a Chinese phase II study (NEOCAP) reported in The Lancet Oncology, Yu et al found that neoadjuvant camrelizumab plus apatinib produced promising complete response rates in patients with locally advanced microsatellite instability–high or mismatch repair–deficient colorectal cancer. Study ...
Multiple Myeloma: Using Absolute Lymphocyte Count to Predict Outcomes After CAR T-Cell Therapy
A simple blood test that measures lymphocyte counts may predict whether patients with relapsed multiple myeloma are going to respond well to chimeric antigen receptor (CAR) T-cell immunotherapy, according to research published by Saldarriaga et al in Blood Advances. The study found that patients...
Shortening FDA-Mandated CAR T-Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL
Two hallmark toxicities of chimeric antigen receptor (CAR) T-cell therapy may be rare after 2 weeks following infusion in patients with diffuse large B-cell lymphoma (DLBCL), supporting a shorter, more flexible toxicity monitoring period., according to a recent study published by Ahmed et al in...
Eliminating Racial Disparities in Colorectal Cancer Screening
Eliminating racial disparities in colorectal cancer testing may reduce the rate of colorectal cancer incidence and mortality among Black patients in the United States, according to a recent study published by Alagoz et al in the Journal of the National Cancer Institute. Background Although both the ...
Novel Target Identified for Treating HTLV-1–Associated Diseases
Blocking the tyrosine kinase KDR could lead to cell death caused by the degradation of the TAX viral protein, thereby treating diseases associated with human T-cell leukemia virus type 1 (HTLV-1), according to a recent study published by Mohanty et al in Nature Communications. Background HTLV-1 is...
AACR, ASA, FDA Outline Considerations for Overall Survival Analyses in Clinical Trials
Experts from the American Association for Cancer Research (AACR), American Statistical Association (ASA), and U.S. Food and Drug Administration (FDA) have outlined considerations for clinical trial designs to enhance the collection and analysis of overall survival data in the context of modern-day...
Tailored Dose-Dense Adjuvant Chemotherapy in High-Risk Early Breast Cancer
As reported in the Journal of Clinical Oncology by Matikas et al, the prespecified end-of-study analysis of the European phase III PANTHER trial showed significant improvements in outcomes with tailored dose-dense vs standard adjuvant chemotherapy in patients with high-risk early breast cancer. As...
Liquid Biopsy May Enable Monitoring of Disease Evolution in Patients With Metastatic Prostate Cancer
DNA/RNA material contained in circulating extracellular vesicles secreted into the blood stream by tumor cells may capture cancer genomics and transcriptomic evolution in patients with metastatic prostate cancer, according to a recent study published by Casanova et al in Cancer Cell. Background...
Panel Issues First Guidelines to Prevent Anal Cancer in Patients With HIV
Researchers have introduced the first screening and treatment recommendations to prevent anal cancer in patients with the human immunodeficiency virus (HIV), according to new guidelines based on the results of a 2022 study published by Palefsky et al in The New England Journal of Medicine....
